Biosimilar Pathway Quickly Becoming Crowded In U.S.
This article was originally published in The Pink Sheet Daily
Executive Summary
Interactive chart of growing 351(k) pipeline shows that while Phase III is dominated by big players, pure-play biosimilar companies are beginning to emerge.